How The Fda Let Halcion Slip Through

It admits it didn't adequately examine Upjohn's data

In early 1992, Food & Drug Administration investigator D. Mich-ael Erspamer was hot on the trail of pharmaceutical giant Upjohn Co. The question: Had the company intentionally withheld key information about problems with its blockbuster sleeping pill, Halcion, from the FDA? The controversial drug had recently been banned in Britain because of such side effects as memory loss, vertigo, and depression. On Mar. 17, 1992, Erspamer was about to pick up a slew of new documents from Upjohn. "We suspected something improper," he recalls.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.